IL326152A - צורות מצב מוצק של gusacitinib - Google Patents

צורות מצב מוצק של gusacitinib

Info

Publication number
IL326152A
IL326152A IL326152A IL32615226A IL326152A IL 326152 A IL326152 A IL 326152A IL 326152 A IL326152 A IL 326152A IL 32615226 A IL32615226 A IL 32615226A IL 326152 A IL326152 A IL 326152A
Authority
IL
Israel
Prior art keywords
gusacitinib
solid state
state forms
forms
solid
Prior art date
Application number
IL326152A
Other languages
English (en)
Original Assignee
Libertas Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Libertas Bio Inc filed Critical Libertas Bio Inc
Publication of IL326152A publication Critical patent/IL326152A/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL326152A 2023-07-27 2024-07-26 צורות מצב מוצק של gusacitinib IL326152A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2023/109559 WO2025020171A1 (en) 2023-07-27 2023-07-27 Crystalline forms of a jak/syk inhibitor
PCT/US2024/039745 WO2025024764A1 (en) 2023-07-27 2024-07-26 Solid state forms of gusacitinib

Publications (1)

Publication Number Publication Date
IL326152A true IL326152A (he) 2026-03-01

Family

ID=92626913

Family Applications (1)

Application Number Title Priority Date Filing Date
IL326152A IL326152A (he) 2023-07-27 2024-07-26 צורות מצב מוצק של gusacitinib

Country Status (6)

Country Link
EP (1) EP4750776A1 (he)
KR (1) KR20260074937A (he)
CN (1) CN122206678A (he)
AU (1) AU2024301493A1 (he)
IL (1) IL326152A (he)
WO (2) WO2025020171A1 (he)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026165001A1 (en) * 2025-01-28 2026-08-06 Kadmon Corporation, Llc Combination therapy comprising belumosudil and gusacitinib

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014003981A2 (pt) * 2011-08-23 2017-03-07 Endo Pharmaceuticals Inc compostos de pirimido-piridazinona e seu uso
AR106830A1 (es) * 2015-12-04 2018-02-21 Asana Biosciences Llc Usos de piridazinonas para tratar el cáncer
WO2018187294A1 (en) * 2017-04-03 2018-10-11 Asana Biosciences, Llc Pyrimido-pyridazinone compound combinations, methods, kits and formulations thereof
CN110809471A (zh) 2017-04-28 2020-02-18 阿沙纳生物科学公司 治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型
US20240108633A1 (en) * 2020-12-29 2024-04-04 Onquality Pharmaceuticals China Ltd. Method for preventing or treating disease or condition associated with antitumor agent
US20250171448A1 (en) * 2022-02-23 2025-05-29 Teva Pharmaceuticals International Gmbh Solid state forms of gusacitinib

Also Published As

Publication number Publication date
KR20260074937A (ko) 2026-05-27
WO2025024764A1 (en) 2025-01-30
AU2024301493A1 (en) 2026-03-12
WO2025020171A1 (en) 2025-01-30
CN122206678A (zh) 2026-06-12
EP4750776A1 (en) 2026-06-03

Similar Documents

Publication Publication Date Title
CA215228S (en) Set of earbuds
EP4165031A4 (en) SOLID FORMS OF CYANTRANILIPROL
CA221468S (en) Part of earphone
KR102423280B9 (ko) Sot-mram 면적 최적화 기법
GB202103774D0 (en) Detectiion of Ransomware
GB202411655D0 (en) Application of circHIF1a
IL317645A (he) שיטות להכנת טולברוטיניב
GB202011709D0 (en) Solid dispersion of opicapone
IL304159A (he) תכשיר המכיל bl-8040
IL318553A (he) וריאנטים של tdp-43 עמידים לצבירה
GB202115776D0 (en) Design of engineering components
IL321161A (he) צורות מוצקות של תרכובות נפתירידין
GB2612588B (en) Design of engineering components
IL326153A (he) צורות מצב מוצק של gusacitinib
IL319179A (he) צורות מוצקות של דניפנסטאט
PL4441028T3 (pl) Sól s-oksprenololu
CA3303749A1 (en) Solid state forms of samuraciclib
CA3299990A1 (en) Solid state forms of gusacitinib
CA3299931A1 (en) Solid state forms of gusacitinib
CA3297108A1 (en) Solid state forms of sunvozertinib
CA3294911A1 (en) Solid state forms of rencofilstat
CA3268966A1 (en) Solid state forms of denifanstat
GB202508287D0 (en) Co-amorphous solid forms of flavonoids
GB202215264D0 (en) Use of urolithins
CA234591S (en) Part of windlass